MONOPOST

This brand name is authorized in Germany, Hong Kong SAR China, Ireland, Lithuania, Romania, UK.

Active ingredients

The drug MONOPOST contains one active pharmaceutical ingredient (API):

1	Latanoprost UNII 6Z5B6HVF6O - LATANOPROST
	The active substance latanoprost, a prostaglandin F2α analogue, is a selective prostanoid FP receptor agonist which reduces the intraocular pressure (IOP) by increasing the outflow of aqueous humour. Reduction of the IOP in man starts about three to four hours after administration and maximum effect is reached after eight to twelve hours.
	Read more about Latanoprost

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MONOPOST Eye drops, solution	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01EE01	Latanoprost	S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EE Prostaglandin analogues
Discover more medicines within S01EE01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	10987289, 11886024, 14366934, 14366940
GB	Medicines & Healthcare Products Regulatory Agency	218741, 244668, 381522
HK	Department of Health Drug Office	65985
IE	Health Products Regulatory Authority	53445
LT	Valstybinė vaistų kontrolės tarnyba	1061082, 1069504, 1069505, 1069506, 1083674, 1083675, 1083676
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W59511001, W59511002, W59511003, W59511004, W59511005, W59511006, W59511007, W59511008, W59511009, W59511010, W59511011, W59511012, W59511013, W59511014, W63388001, W63388002